The Best of 2012: Dyax

It's the end of 2012, and that means it's time to take a look back at the year in retrospect. We'll be reading through the naughty and nice lists (we've already checked them twice), counting down the 25 best-performing stocks and the 25 worst-performing stocks in the health care sector this year.

In this segment, Motley Fool health care analysts David Williamson and Max Macaluso take a look at No. 23 on the nice list, Dyax (NASDAQ: DYAX  ) , and how this company left investors with more than a little something extra in their stockings this year.

Over the next two years, Dyax competitor Eli Lilly will see nearly $0.40 of every $1.00 in sales exposed to generic competition protection. How does the company plan to respond to this huge patent cliff? Better yet, what does this mean for investors? In a brand new premium report on Eli Lilly, The Motley Fool's top pharmaceuticals analyst delves into everything investors need to know about the stock today. Simply click here now to claim your copy.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2147095, ~/Articles/ArticleHandler.aspx, 4/19/2014 8:39:31 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement